Floatz logo

Olvimulogene Nanivacirepvec

Advanced Non-squamous Non-small-cell Lung Cancer

Genelux Corporationgene_therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1205 Active assets in the Advanced Non-squamous Non-small-cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Zoledronate
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4BBB
Onartuzumab
Hoffmann-La Roche
Phase 3BBB

View all 50 →

Same molecule, other indications

Olvimulogene Nanivacirepvec is also rated in:

ovarian serous adenocarcinomaDormant
B
Indicative ·
60 / 100
View asset →
Platinum-refractory Ovarian CancerDormant
B
Indicative ·
60 / 100
View asset →
ovarian endometrioid adenocarcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →